Clinical trials: Immune Checkpoint Therapy
Unresectable Hepatocellular Carcinom
Conversion Therapy Using TACE/HAIC With Anti-Angiogenic and Immunotherapy for Initially Unresectable Hepatocellular Carcinoma Achieving Complete Response or Resectability, Followed by Surgery or Continued Systemic Treatment: A Prospective Cohort Study
This is a prospective cohort study designed to evaluate the effectiveness and safety of two post-conversion treatment strategies for patients with initially unresectable hepatocellular carcinoma (uHCC).
- Trial name
- THAI-CONVERT (NCT07206511)
- Volunteers
- 278 people
- Sponsor
- Shanghai Zhongshan Hospital
Lung Cancer, Nonsmall Cell
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
This is a research study to evaluate the safety and effectiveness of tocilizumab in combination with atezolizumab to treat non-small cell lung cancer.
- Trial name
- NCT04691817
- Testing
- Atezolizumab, Tocilizumab
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Melanoma
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
A Phase 2 study investigating the efficacy and safety of ONCOS-102 alone or in combination with balstilimab (a programmed death receptor-1 [PD-1] inhibitor).
- Trial name
- NCT05561491
- Testing
- ONCOS-102, Balstilimab
- Sponsor
- Targovax Oy
Gallbladder Cancer
Envafolimab Combined With GEMOX in First-line Treatment of Advanced GBC
The TOPAZ-1 study compared the advantages and disadvantages of immune checkpoint inhibitor anti-PD-L1 antibody combined with Gem/Cis chemotherapy (Gemcitabine and Cisplatin) and Gem/Cis chemotherapy alone in first-line treatment…
- Trial name
- NCT06013943
- Testing
- Envafolimab+Gemox
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
Gastric Cancer, Gastroesophageal Junction Cancer, Immune Checkpoint Inhibitors (ICIs)
Immune Checkpoint Inhibitors (ICIs) Retreatment in Second-line Treatment of Advanced Gastric Cancer: a Retrospective, Real-world Study
This is a single-center, retrospective, observational, real-world study. We collected general and clinical data of patients with advanced gastric cancer who were admitted to the First Affiliated Hospital of Zhengzhou University…
- Conditions
- Gastric Cancer, Gastroesophageal Junction Cancer, Immune Checkpoint Inhibitors (ICIs), Second-line, Retreatment
- Trial name
- NCT06814548
- Testing
- ICIs(Immune checkpoint inhibitors)
- Volunteers
- 200 people
- Sponsor
- Yongxu Jia
Urinary Bladder Neoplasms
Comprehensive Bladder Preservation Therapy on Patients With Muscle Invasive Bladder Cancer
Nowadays, Immune Checkpoint Inhibitor (ICI) has become one of the new drugs for the treatment of advanced uroepithelial carcinoma.
- Trial name
- CBPTMI (NCT05445648)
- Testing
- Tislelizumab Injection, Transurethral resection of bladder tumor, Adjuvant radiotherapy
- Where
- China
- Volunteers
- 65 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Non-Small Cell Lung Cancer, Electroacupuncture
Electroacupuncture Combined With Immune Checkpoint Inhibitors as Adjuvant Therapy After Surgery for Early-stage Non-small Cell Lung Cancer
Postoperative immunoadjuvant therapy has been proven to significantly reduce the risk of recurrence after resectable NSCLC, and has become a new standard of postoperative adjuvant therapy for stage II-III NSCLC.
- Conditions
- Non-Small Cell Lung Cancer, Electroacupuncture, Immune Checkpoint Inhibitors
- Trial name
- NCT07034326
- Testing
- Electroacupuncture combined with immunotherapy, Zilongjin tablet combined with immunotherapy, Immunotherapy
- Where
- China
- Volunteers
- 405 people
- Sponsor
- Kong Fanming
Melanoma, Effects of Immunotherapy
Trial of SBRT With Concurrent Ipilimumab in Metastatic Melanoma
The prognosis of advanced metastatic melanoma remains poor although a breakthrough has been achieved with the novel anti-CTLA-4 treatment (ipilimumab) for a subset of patients.
- Conditions
- Melanoma, Effects of Immunotherapy, Adverse Effect of Radiation Therapy
- Trial name
- NCT02406183
- Testing
- Stereotactic body radiotherapy (SBRT), Ipilimumab
- Where
- Belgium
- Volunteers
- 13 people
- Sponsor
- Radiotherapie
Cancer
A Study of ApricityRx™ for Management of IR-AEs in Patients on Immuno-Oncology Therapy
Study of ApricityRx™ for Management of IR-AEs for patients on I-O therapy. Patients currently receiving immunotherapy will be asked to consent to participate in ApricityRx software platform mobile telephone application to report…
- Trial name
- NCT04571398
- Testing
- ApricityRx mobile application
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Apricity Health, Inc
Colon Cancer
Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon Cancer（Neo-Color）
The goal of this clinical trial is to evaluate the efficacy and safety of conversion therapy using radiotherapy combined with systemic treatment (chemotherapy + immune checkpoint inhibitors) for patients with pMMR/MSS T4M0 stage…
- Trial name
- NCT06949111
- Testing
- radiotherapy, CAPOX, Capecitabine
- Where
- China
- Volunteers
- 128 people
- Sponsor
- Hebei Medical University Fourth Hospital
Neoplasms, Drug Therapy
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study
The population receiving immunotherapy is heterogeneous. Multiple factors, including combination treatment modalities, influence the immune response, and survival outcomes also vary among individuals receiving immunotherapy.
- Conditions
- Neoplasms, Drug Therapy, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT07665697
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sichuan University
Carcinoma, Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma
Study to Evaluate the Safety and Efficacy of Oral NRC-2694-A in Combination With Paclitaxel in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma, Who Progressed on or After Immune Checkpoint Inhibitor Therapy
This is a Phase 2, open-label, multicenter, single-arm study of NRC-2694-A in combination with paclitaxel in patients with R/M HNSCC with progression on or after ICI therapy.
- Trial name
- NCT05283226
- Testing
- NRC-2694-A, Paclitaxel
- Where
- 13 sites in United States, India
- Volunteers
- 21 people
- Sponsor
- NATCO Pharma Ltd.
Non-small Cell Lung Cancer (NSCLC), Squamous Oesophageal Cancer
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
This clinical trial is looking at two new vaccines called ChAdOx1-MAGEA3-NYESO, MVA-MAGEA3 and MVA-NYESO given with patients' standard of care treatment (chemotherapy and an immune checkpoint inhibitor).
- Trial name
- NCT04908111
- Testing
- ChAdOx1-MAGEA3-NYESO (Route = IM injection, Dose = 5×10^10 vp), MVA-MAGEA3 (Route = IM injection, Dose = 1.3×10^8 pfu), Standard of care treatment
- Where
- 9 sites in United Kingdom
- Volunteers
- 15 people
- Sponsor
- Cancer Research UK
Cancer, Psychosocial Functioning
Body Composition and Psychosocial Factors in ICI-Treated Cancer Patients
Evaluation of the effects of body composition, psychosocial factors, and drug-related problems on clinical progression (such as toxicity, treatment response, and quality of life) in cancer patients treated with immune checkpoint…
- Conditions
- Cancer, Psychosocial Functioning, Treatment Side Effects, Cachexia
- Trial name
- NCT07130981
- Where
- Turkey (Türkiye)
- Volunteers
- 200 people
- Sponsor
- Hacettepe University
Head and Neck Squamous Cell Carcinoma
Becotatug Vedotin Plus PD-1 Inhibitor for Head and Neck Squamous Cell Carcinoma
This is a prospective, open-label, non-randomized, two-cohort, single-arm Phase 2 study in adults with unresectable or recurrent/metastatic head and neck squamous cell carcinoma, excluding nasopharyngeal carcinoma.
- Trial name
- NCT07683507
- Testing
- Becotatug Vedotin Combined with PD-1 Inhibitor
- Volunteers
- 60 people
- Sponsor
- Feng Liu
Urogenital Cancer
Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer
This study is being carried out to see if the drug atezolizumab can reduce the size of tumours in patients with types of urothelial cancer before surgery.
- Trial name
- ABACUS-2 (NCT04624399)
- Testing
- Atezolizumab
- Where
- United Kingdom
- Volunteers
- 32 people
- Sponsor
- Queen Mary University of London
NSCLC (Non-small Cell Lung Cancer)
Oral Paclitaxel Solution With Immunotherapy and Concurrent SBRT as Neoadjuvant Treatment for Older Adults With NSCLC
his multicenter, open-label, single-arm phase I/II trial will evaluate the safety, tolerability, and preliminary efficacy of oral paclitaxel solution combined with an immune checkpoint inhibitor and concurrent stereotactic body…
- Trial name
- NCT07754812
- Testing
- Oral Paclitaxel Solution, PD-1/PD-L1 inhibitor, Stereotactic Body Radiotherapy (SBRT)
- Where
- 5 sites in China
- Volunteers
- 78 people
- Sponsor
- Shanghai Pulmonary Hospital, Shanghai, China
Lung Neoplasms, Tumor Immune Microenvironment
Association of BAL Fluid T-Cell Immune Activity With Tumor PD-L1 Expression and Its Prognostic Value: A Prospective Observational Study
This prospective observational study aims to evaluate whether immune profiles of T-cell subsets in bronchoalveolar lavage fluid can complement tumor PD-L1 expression, assessed by immunohistochemistry in tumor tissue specimens, in…
- Trial name
- NCT07331701
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Advanced Solid Tumor
Study on the Treatment of Advanced Malignant Solid Tumor With Revottack and PD-1 Inhibitor
This is a one arm, open clinical pharmacological exploration study initiated by researchers to evaluate the safety and effectiveness of vesicular stomatitis oncolytic virus injection (Revottack) combined with PD-1 inhibitor in…
- Trial name
- NCT05644509
- Testing
- Oncolytic Virus Injection（Revottack）+PD-1
- Where
- China
- Volunteers
- 10 people
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
Metastatic Cancer, Solid Tumors
Arginase Inhibitor INCB001158 as a Single Agent and in Combination With Immune Checkpoint Therapy in Patients With Advanced/Metastatic Solid Tumors
This study is an open-label Phase 1/Phase 2 evaluation of INCB001158 as a single agent and in combination with immune checkpoint therapy in patients with advanced/metastatic solid tumors.
- Conditions
- Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer
- Trial name
- NCT02903914
- Testing
- INCB001158, Pembrolizumab
- Where
- 20 sites in United States, Italy and 2 more
- Volunteers
- 260 people
- Sponsor
- Incyte Corporation